BOSC23

{{Short description|Human cell line}}

BOSC 23 is a human kidney cell line developed by Warren Pear in David Baltimore's lab{{Cite web|url=http://www.bio.net/bionet/mm/methods/2000-December/086646.html|title = BOSC 23 cell line}} that was derived from the 293T cell line.{{cite journal |vauthors=Pear WS, Nolan GP, Scott ML, Baltimore D |title=Production of high-titer helper-free retroviruses by transient transfection |journal=Proc. Natl. Acad. Sci. USA |volume=90 |issue=18 |pages=8392–8396 |date=15 Sep 1993 |pmid=7690960 |pmc=47362 |doi=10.1073/pnas.90.18.8392|bibcode=1993PNAS...90.8392P |doi-access=free }}{{cite book |last1=Baker |first1=Andrew H. |title=Vascular Disease: Molecular Biology and Gene Transfer Protocols |date=1 February 2008 |publisher=Springer Science & Business Media |isbn=978-1-59259-247-0 |url=https://books.google.com/books?id=VsMLow12OHQC&dq=BOSC23&pg=PA336 |language=en}} The main use of BOSC 23 is the production of recombinant retroviruses; it stably expresses Moloney murine leukemia virus proteins and when transiently transfected with recombinant retroviral vector DNA, produces high titers of infectious retroviral particles. The cell line does not produce detectable replication-competent virus, an important safety feature.{{cn|date=April 2021}}

BOSC 23 carries neomycin/G418 resistance derived from its parental line 293T, and also hygromycin and mycophenolic acid (gpt) resistance. It should be maintained under gpt selection.{{cn|date=April 2021}}

This cell line is a model for cancer research, with emphasis on the lack of activated Src protein.Goh YM, Cinghu S, Hong ETH et al. Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm. The Journal of Biochemistry vol.285, no.13, pp.10122-10129, March 2010